SYNAPSE provides cutting edge developmental research and tailored products for the treatment of Haemostasis and Thrombosis. We provide a critical commercial bridge between the health care research sector (i.e., biochemistry/molecular biology) and the pharmaceutical and clinical sciences product industry. We partner with pharmaceutical and healthcare businesses and deliver tools used to measure antiplatelet drugs and clotting factor inhibitors, define their effects on animals and humans (both in vitro and in vivo environments) and we create diagnostic procedures based on specific coagulation interactions. SYNAPSE supplies cutting edge analytics on the Thrombin generating process of the body’s platelet plasma environment and use the bloodstream as a primary diagnostic tool and a pharmaceutical delivery system. **Selected Publications** - Leunissen TC, Wisman PP, van Holten TC, de Groot PG, Korporaal SJ, Koekman AC, Moll FL, Teraa M, Verhaar MC, de Borst GJ, Urbanus RT, Roest M. The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays. *Platelets*. 2016 Nov 25:1-9. - Basir A, de Groot P, Gründeman PF, Tersteeg C, Maas C, Barendrecht A, van Herwaarden J, Kluin J, Moll F, Pasterkamp G, Roest M. In Vitro Hemocompatibility Testing of Dyneema Purity Fibers in Blood Contact. *Innovations (Phila)*. 2015 May-Jun;10(3):195-201. - Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG, Roest M. Active Von Willebrand Factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. *Blood*. 2014 Apr 3;123(14):2153-6. - Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C. Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy. *Circulation*. 2014 Mar 25;129(12):1320-31. - Tersteeg C, Heijnen HF, Eckly A, Pasterkamp G, Urbanus RT, Maas C, Hoefer IE, Nieuwland R, Farndale RW, Gachet C, de Groot PG, Roest M. FLow-Induced PRotrusions (FLIPRs): A Platelet-Derived Platform for the Retrieval of Microparticles by Monocytes and Neutrophils. *Circ Res*. 2014 Feb 28;114(5):780-91. - van Holten TC, Bleijerveld OB, Wijten P, de Groot PG, Heck AJ, Barendrecht AD, Merkx TH, Scholten A, Roest M. Quantitative proteomics analysis reveals similar release profiles following specific PAR-1 or PAR-4 stimulation of platelets. *Cardiovasc Res*. 2014 Jul 1;103(1):140-6. - Miszta A, Pelkmans L, Lindhout T, Krishnamoorthy G, de Groot PG, Hemker CH, Heemskerk JW, Kelchtermans H, de Laat B. Thrombin-Dependent Incorporation of Von Willebrand Factor into a Fibrin Network. *J Biol Chem*. 2014 - Pelkmans L, Miszta A, Al Dieri R, de Laat B, Kelchtermans H. Thrombin generation in the presence of platelets is sensitive to the activation status of von Willebrand factor. *Thromb Haemost*. 2014 Oct 2;113(1). - de Laat B. *Blood*. Antibodies in APS with competing interest. 2014 May 29;123(22):3373-4 - Ninivaggi M, Kelchtermans H, Kuijpers MJ, Hemmeryckx B, Heemskerk JW, Lindhout T, Hoylaerts MF, de Laat B. Whole blood thrombin generation in Bmal1-deficient mice. *Thromb Haemost*. 2014 Aug;112(2):271-5 - Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. *J Thromb Haemost*. 2014 May;12(5):792-5
Synapse Research Institute developed a flow cytometry-based whole blood platelet activation test (WB-PACT) which measures platelet activation in response to specific agonists. The test is optimized for (1) the GPVI agonist collagen related peptide (CRP), (2) the PAR-1 agonist thrombin receptor activating peptide (TRAP) and (3) the P2Y12 receptor agonist ADP. Simultaneously, the activation of GPIIb/IIIa and the expression of P-selectin on the platelet surface is quantified, correlating with the aggregation and granule release potential of platelets, respectively. The test is also very sensitive for "in vitro" evaluation of the impact of medication or antibodies on platelet response.
Calibrated TG is the solution for the prediction of (venous) thrombosis risk in patients with atrial fibrillation, cancer, APC-resistance and inflammatory disorders. Furthermore, calibrated TG gives the most complete view of coagulation in patients with high bleeding risk.
Thrombin generation can be done in plasma, platelet rich plasma and whole blood.
Synapse has developed a thrombin generation assay, to study the impact of heparin on the coagulation profile of an individual patient.
Tests to determine Antiphospholipid syndrome
Whole blood haemostasis test to the tolerance of exogeneous implants or stents.
Synapse B.V. has not received any reviews.
Synapse B.V. has not received any endorsements.